Peter de Nully Brown

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper et al. · The Lancet Oncology · 2011 · 796 citations

Hematological Malignancy, Lymphoid Neoplasia, 6-Year Results +9

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2008 · 619 citations · Full text

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

Francesco d’Amore, Thomas Relander, Grete F. Lauritzsen et al. · Journal of Clinical Oncology · 2012 · 584 citations

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

Simon R. Bramhall, J Schulz, John Nemunaitis et al. · British Journal of Cancer · 2002 · 559 citations · Full text